Company Information

  

Address: ONE FIRST AVENUE
PARRIS BUILDING 34, NAVY YARD PLAZA 
City: BOSTON 
State: MA 
Zip Code: 02129 
Telephone: 617-259-1970 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression and control technology to deliver DNA for the treatment of cancer. ZIOPHARM's technology platform employs Intrexon Corporation's RheoSwitch Therapeutic System® to turn on and off, and precisely modulate, gene expression at the cancer site in order to improve the therapeutic index. This technology is currently being evaluated in Phase 2 clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma. Multiple new INDs for new targets using similar technology are expected in 2014 and 2015. ZIOPHARM is also developing novel small molecules as potential cancer therapeutics.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-0.50NAN/E
03/2017-1.38NAN/E
12/2016-1.32NAN/E
09/2016-1.28NAN/E
06/2016-1.30NAN/E
03/2016-0.36NAN/E
12/2015-0.96NAN/E
09/2015-0.99NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.28Total Liab/Total Assets0.55
Net Inc/Total Assets-1.55Total Liab/Inv Cap0.64
Net Inc/Inv Cap-1.83Total Liab/Comm Equity0.10
Pretax Inc/Net Sales-24.09Interest Coverage RatioNA
Net Inc/Net Sales-24.09Curr Debt/EquityNA
Cash Flow/Net Sales-8.50LTD/Equity-0.01
SG&A/NetSales2.10Total Debt/Equity-0.01
Asset Utilization   Liquidity  
Net Receivables Turnover29.38Quick Ratio6.63
Inventory TurnoverNACurrent Ratio6.63
Inventory Day SalesNANet Rec/Curr Assets0.00
Net Sales/Work Cap0.08Inv/Curr AssetsNA
Net Sales/PP&E8.14  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) 1.60 1.60 1.60 1.60
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 3.78 3.60 3.32 3.54
Operating Income -13.01 -13.97 -11.11 -10.91
Interest Exp NA NA NA NA
Pretax Income -12.86 -15.49 -11.22 -10.85
Other Income 0.15 -1.52 -0.11 0.06
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -12.86 -15.49 -11.22 -10.85

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 97.19 66.45 81.05 94.68
Receivables - Total 0.04 0.07 0.02 0.03
Inventories - Total NA NA NA NA
Total Current Assets 125.13 92.75 104.88 115.68
Net Property, Plant & Equipment 1.06 1.12 0.84 0.83
Total Assets 126.81 94.49 106.35 117.12
Liabilities        
Accounts Payable 9.44 10.91 9.27 9.18
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 15.99 17.46 15.81 15.74
Long-Term Debt 2.48 2.47 0.86 0.69
Total Liabilities 56.85 59.96 58.33 59.73
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA 0.00
Common Stock 0.14 0.13 0.13 0.13
Retained Earnings -686.47 -673.61 -658.00 -646.77
Treasury Stock NA NA NA NA
Total Stockholders' Equity -64.27 -94.90 -77.30 -64.42
Total Liabilities and Stockholders' Equity -7.42 -34.95 -18.97 -4.69

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -15.52 -14.28 -13.06 -14.11
Net Cash Provided by Investing Activities -0.03 -0.36 -0.08 -0.21
Net Cash Provided by Financing Activities 46.30 0.03 -0.48 0.00

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20120.80-96.13-1.22
12/20130.80-57.11-0.66
12/20141.37-31.78-0.31
12/20154.33-120.09-0.96
12/20166.86-165.30-1.32
Growth Rates71.13----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/1714260,60042.69




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.